ABSTRACT
This chapter describes the clinical application of T-cell-receptor (TCR) peptides for inducing systemic autoregulation in humans with multiple sclerosis (MS). The human trials represent a direct extension of work carried out concomitantly in rodents with experimental autoimmune encephalomyelitis (EAE), a paralytic disease with a number of similarities with MS. As there has been considerable practical knowledge gained from the EAE model, we include a discussion of relevant preclinical data.
